Checkpoint Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue - related party
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (loss):
Interest income
Loss on common stock warrant liabilities
Gain (loss) on common stock warrant liabilities
Foreign currency exchange loss
Total other income (loss)
Net Loss
Loss per Share:
Basic and diluted net loss per common share outstanding
Basic and diluted weighted average number of common shares outstanding
Basic net loss per Class A common share and common share outstanding (in dollars per share)
Diluted net loss per Class A common share and common share outstanding (in dollars per share)
Basic weighted average number of Class A common shares and common shares outstanding (in shares)
Diluted weighted average number of Class A common shares and common shares outstanding (in shares)

Comments